Angiotensin-converting enzyme insertion/deletion gene polymorphisms is associated with risk of glioma in a Chinese population

Abstract

Introduction:The insertion/deletion (I/D) polymorphism of the angiotensin-converting enzyme (ACE) gene has recently been linked to the pathogenesis and progression of human cancers. The aim of this study was to evaluate the potential association between ACE I/D polymorphism and glioma in a Chinese population. Materials and methods: A case-control study involving patients with 800 glioma and 800 controls was conducted. Polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) assay was applied to assess the ACE I/D genotypes. Results: Glioma cases had a significantly higher frequency of DD genotype [odds ratio (OR) = 1.61, 95% confidence interval (CI) = 1.12, 2.32; p = 0.01] than controls. When stratified by the grade of glioma, cases with WHO IV glioma had a significantly higher frequency of DD genotype (OR = 1.51, 95% CI = 1.03, 2.21; p = 0.03). When stratified by the histology of glioma, there was no significant difference in the distribution of each genotype. Conclusion: Our study suggested that the ACE DD genotype was associated with a higher glioma risk in this Chinese population. To the best of our knowledge, this is the first report describing the potential association between ACE I/D polymorphism and glioma. Additional studies are needed to confirm this finding.

Angiotensinogen rs5050 germline genetic variant as potential biomarker of poor prognosis in astrocytoma

“…In another study, Lian et al . suggested the insertion/deletion (I/D) genetic variant of the ACE gene as a risk biomarker for glioma, and performed a case-control study in a Chinese population, which showed that glioma patients had a significantly higher prevalence of the ACE DD-genotype detected in blood [ 51 ]. The AGT rs5050 is so far the only RAS component that is simultaneously related to prognosis and identified by a blood test, which would be both valuable and practical features for a biomarker in a clinical setting.…”

The genetic polymorphisms of angiotensin converting enzyme insertion/deletion and glioma susceptibility: A meta-analysis

“…For the association between ACE I/D polymorphism and glioma, four studies including 1110 cases and 2335 controls were included for the analysis. Overall, the meta-analyses demonstrated no 8 China Chinese 800/800 Healthy subjects Pandith et al 9 India Indian 112/141 Healthy subjects Benenemissi et al 10 Algeria Algerian 36/195 Healthy subjects significant association between ACE I/D polymorphism and glioma risk. As shown in Figure 2(a), compared with ACE ID/II genotype, subjects with DD genotype showed a non-significant risk for glioma (OR 1.96; 95%CI 0.73 to 5.27; p = 0.18).…”

“…16 Recently, Pandith et al 9 reported that ACE DD genotypes were highly presented in glioma cases 26.8% versus 10.6% in controls and conferred 5-fold risk for predisposition in glioma cases. Lian et al 8 also found that glioma cases had a significantly higher frequency of DD genotype than controls. Benenemissi et al 10 reported that ACE DD genotype was highly presented in glioma cases than controls and conferred 3.64-fold risk for predisposition in glioma cases compared with ID genotype.…”

“…Thus, four studies 7 – 10 including 1110 cases and 1335 controls on ACE I/D polymorphism and glioma risk were included in this meta-analysis. All the studies were case-control studies and the distributions of the genotypes in the control populations were consistent with HWE in all the four studies ( Table 1 ).…”

“… 6 In the recent years, ACE I/D genetic polymorphisms has been concerned in the susceptibility of glioma. 7 – 10 However, the previous reports were inconsistent. Therefore, our present study aimed to perform a meta-analysis to assess the association between ACE I/D polymorphisms and glioma susceptibility.…”